Navigation Links
VG Life Sciences, Inc. Announces Management Changes

SANTA BARBARA, Calif., July 18, 2013 /PRNewswire/ -- VG Life Sciences, (OTC Pink: VGLS) a biotechnology company, announces alterations in its corporate management and management structure.

Interim CEO & President

John Tynan has been named Interim CEO & President of VG Life Sciences, inc, effective immediately. Mr. Tynan started TynanGroup, Inc. in 1991 and grew it to successful company as a leader in real estate development services across the country, overseeing more than $4 billion of construction. TynanGroup was on INC Magazine's list of the fasting growing companies and today includes a host of sister companies including MedBridge Development Company, LLC and Anchor Point IT Solutions. Prior to starting TynanGroup, he was Vice President for Hyatt Development Corporation where he oversaw $1.5 Billion project expenditures and over 9,000 people. Mr. Tynan has a BS in Civil Engineering from the University of Illinois and a MBA in finance from DePaul University. "My focus is on achieving specific goals to increase shareholders' value and support our exceptional research team," said Tynan. Haig Keledjian will stay on as Chairman of the Board and VP of Intellectual Property and Product Development.

For more information on the goals and direction of the company as well as the new management structure of VG Life Sciences, please see the July 18th, 2013 investor letter, which can be downloaded from the company site and viewed here.

About VG Life Sciences Inc.
Santa Barbara, California-based VG Life Sciences Inc., formerly known as Viral Genetics, is a biotechnology company focused on discovering and developing drug therapies for cancer, infectious diseases, and autoimmune disorders.  VGLS controls over 50 US and international patents and pending patents protecting its exclusive biotech platform technologies. For more information, visit

Alexandria Sumner, Corporate Communications
VG Life Sciences, Inc.
Phone:  (805) 679-6763

SOURCE VG Life Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Islet Sciences, Inc. Selects NeoStems Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing
2. Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA
3. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
4. Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine
5. Regado Biosciences, Inc. to Present at Needham & Companys 11th Annual Healthcare Conference in New York, NY
6. Intellect Neurosciences, Inc. to Present at Neurotech Investing and Partnering Conference
7. Pressure BioSciences, Inc. Reaches Agreement with Investors on Initial $600,000 Tranche of $1.2 Million Above-Market Private Placement; Proceeds to Support Continued Commercialization of PCT Product Platform
8. Pressure BioSciences, Inc. Continues Global Sales Reach Expansion with Distribution Agreements for China, Vietnam, Laos, Cambodia, Australia, and New Zealand
9. Jaipal Reddy, Honble Minister of Science and Technology & Earth Sciences, Inaugurates the International Bioenergy Summit in Delhi
10. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
11. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
Post Your Comments:
(Date:10/12/2017)... NY (PRWEB) , ... October 12, 2017 , ... ... of Sciences today announced the three Winners and six Finalists of the 2017 ... given annually by the Blavatnik Family Foundation and administered by the New York ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the first-ever genomics analysis platform specifically designed for life science researchers to ... of pioneering researcher Rosalind Franklin, who made a major contribution to the ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... announced today it will be hosting a Webinar titled, “Pathology is going digital. ... Associates , on digital pathology adoption best practices and how Proscia improves lab ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and ... of osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
Breaking Biology News(10 mins):